Core Findings - An international research team published a study in *Nature* indicating that fine particulate matter pollution may increase the risk of cancer gene mutations in non-smokers, leading to a higher likelihood of lung cancer compared to the effects of secondhand smoke [1] Group 1: Research Overview - The study was conducted by researchers from the National Institutes of Health and the University of California, San Diego, analyzing tumor samples from 871 non-smoking lung cancer patients across 28 regions globally [1] - The research found a strong correlation between fine particulate matter pollution, including vehicle emissions and industrial discharges, and the increase in cancer-related gene mutations in non-smokers [1] Group 2: Genetic Implications - The study identified mutations in the TP53 gene and various other mutations previously associated with smoking, which were linked to exposure to air pollution [1] - Air pollution was found to cause premature shortening of telomeres, leading to early cellular aging and potentially accelerating tumor progression [1] Group 3: Comparative Analysis - The findings suggest that air pollution has a higher likelihood of inducing gene mutations in non-smokers compared to secondhand smoke [1]

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit due to allegations of providing misleading information regarding its clinical trials, particularly concerning the safety of its gene therapy product RP-A501 for Danon disease [3][4]. Group 1: Lawsuit Details - The class action lawsuit is titled Ho v. Rocket Pharmaceuticals, Inc. and covers purchasers of Rocket Pharmaceuticals securities from February 27, 2025, to May 26, 2025 [1]. - The lawsuit alleges that Rocket Pharmaceuticals and a top executive violated the Securities Exchange Act of 1934 by concealing material adverse facts about the safety and clinical trial protocol of RP-A501 [3]. - It is claimed that the company failed to disclose serious adverse events, including the death of a participant, which occurred after a protocol amendment that introduced a new immunomodulatory agent [3][4]. Group 2: Impact on Stock - Following the announcement of a clinical hold by the U.S. Food and Drug Administration on May 27, 2025, due to a serious adverse event, Rocket Pharmaceuticals' stock price experienced a decline [4]. Group 3: Legal Process - Investors who purchased Rocket Pharmaceuticals securities during the class period can seek appointment as lead plaintiff in the lawsuit, which allows them to act on behalf of other class members [5]. - The lead plaintiff can choose a law firm to represent the class, and participation as lead plaintiff does not affect the ability to share in any potential recovery [5]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6]. - The firm has been ranked 1 in the ISS Securities Class Action Services rankings for four out of the last five years, indicating its strong track record in obtaining monetary relief for investors [6].

Core Viewpoint - India is likely to allow the import of genetically modified animal feed from the United States as part of a trade agreement [1] Group 1 - The potential trade agreement may enhance agricultural trade between India and the United States [1] - This move could signify a shift in India's stance on genetically modified organisms (GMOs) in agriculture [1] - The import of genetically modified animal feed may lead to increased efficiency and productivity in India's livestock sector [1]

7月2日，人大附中经开学校举办"王永志实验班"启动仪式暨载人航天主题讲座。王永志夫人王丹阳 为"王永志实验班"授牌；中国载人航天应用与测控专家、原王永志院士技术助手王朋受聘为"王永志实 验班"名誉班主任，并带来王永志院士科学精神讲座。 永志班将强化航天科技领域拔尖人才培养 首届"王永志实验班"将于新学期正式开班 仪式上，王永志夫人王丹阳为"王永志实验班"授牌，并以王永志一生以国家需求为己任，无私奉献于航 天事业的精神勉励现场同学们。"在他的一生中，除了上清华大学是出于自己的志愿，其他所有的志愿 和工作都是国家让他干什么，他就干什么，要干就干好。我希望大家能从现在开始，树立自己的人生 观、世界观。" 课程体系以国家课程标准为根基，围绕学科教学大纲核心内容，重点引入当今科技前沿知识，帮助学生 了解最新科技发展。将航天航空、人工智能、芯片半导体、生物基因、新能源、海洋极地、量子科技等 突破性成果转化为适龄化的教学资源，构建起"扎实基础+前瞻视野"的创新型教学模式。 在实践和拓展课程中，永志班将与清华大学、北京航空航天大学、北京理工大学、哈尔滨工业大学等航 天强校合作，强化航天科技（000901）领域拔尖人才培养，夯 ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 耳聋 是人类最常见的感官障碍，先天性耳聋影响了全世界大约 2600 万人，其中高达 60% 的病例是由基因突变引起。 常染色体隐性遗传耳聋9型 （ DFNB9 ） ，是由 编码 耳畸蛋白 （Otoferlin） 的 OTOF 基因突变导致的感音神经性耳聋，占 遗传性耳聋的 2%-8%。耳畸蛋白能使内耳毛细胞响应声音刺激而释放神经 递质，激活听觉神经元，当其功能受损时，声音信号将无法被传达到大脑，从而导致感音神经性耳聋。 此前， 复旦大学附属眼耳鼻喉科医院 舒易来 教授 、 东南大学 附属中大医院 柴人杰 教授等 已经在低龄儿童患者中证实了 AAV 基因治疗 能够安全且有效地恢 复 DFNB9 患者的听力，相关研究发表于《 柳叶刀 》、 Nature Medicine 、 Advanced Science 等期刊。但还有一些关键科学问题亟待解答—— 大龄 DFNB9 患者是否能够受益于 AAV 基因疗法？是否存在最佳治疗年龄窗口？ 2025 年 7 月 2 日 ， 东南大学 附属中大医院 柴人杰 教授联合加州大学欧文分校 曾凡钢 教授，山东省第二人民医院 （山东省耳鼻喉医 ...

《措施》明确，深圳将在产业集聚区设立注册指导服务站，提供靠前服务。真实世界数据应用将拓展至 人工智能医疗、中医药等前沿领域，加速产品上市进程。 提升临床试验服务效能 《措施》提出，深圳将加快建设大湾区国际临床试验中心，统筹大湾区临床试验资源，支持粤港澳大湾 区国际临床试验中心与粤港澳大湾区国际临床试验所协同发展，构建国际化临床试验网络体系。深圳将 优化市内临床试验院内流程，争取将临床试验启动前机构内部整体用时压缩至25周内，支持符合条件的 罕见病用创新药和创新医疗器械向国家药品监督管理局申请减免临床试验。研究型医院可设立专项床 位，其临床研究不纳入病床使用效益考核。 全面支持医药研发和引进，大力推动人工智能在生物制造及药械研发领域应用，加快建设大湾区国际临 床试验中心……日前，深圳市发展和改革委员会等四部门联合印发《深圳市全链条支持医药和医疗器械 发展若干措施》，推出32项政策措施，旨在构建覆盖基础研究、临床转化、生产制造、市场应用的完整 产业生态链。 政策支持力度空前 从覆盖范围和政策亮点来看，深圳此次推出的32项政策措施，聚焦临床前研究、临床试验、注册审批、 生产制造、入院推广等医药和医疗器械产业发展全链 ...

Core Insights - The Beijing Brain Science and Brain-like Research Institute is making significant advancements in brain-machine interface (BMI) technology, which is crucial for improving the quality of life for patients with severe neurological conditions [2][4][6] - The institute has developed the "North Brain No. 1" system, which is the first high-throughput, wireless, fully implanted BMI system with over 100 channels, and it has entered clinical verification stages [2][4] - The research focuses on four main areas: brain cognitive principles, major brain diseases, new technologies in neuroscience, and neural decoding and computation [6][7] Group 1: Brain-Machine Interface Developments - The "North Brain No. 1" system allows for real-time decoding of brain signals, enabling patients to control devices through thought, with a notable accuracy of 63% in decoding common phrases for patients with speech impairments [3][4] - The institute has successfully completed surgeries for five patients with spinal cord injuries and ALS, demonstrating significant improvements in motor functions and the ability to perform tasks previously impossible [3][4] - The upcoming "North Brain No. 2" system aims to implant electrodes deeper into brain tissue for more precise signal capture, enhancing the control capabilities for patients [4] Group 2: Gene Therapy Innovations - The institute is also pioneering gene therapy techniques to treat conditions such as severe epilepsy and vision loss, with a new drug that can be injected directly into the epilepsy focus area to control seizures while preserving normal neural function [7] - A novel light-sensitive protein has been developed for visual restoration in patients with retinal diseases, showing significant improvements in vision for treated patients [6][7] - The institute has established a biotechnology company to facilitate the transition from basic research to clinical applications, aiming to shorten the time for technology commercialization [7]

Group 1 - The research team has developed a detailed "molecular battle map" of human immune cells responding to transplanted pig kidney tissues, marking a significant breakthrough in overcoming xenotransplantation immune rejection issues [1][2] - The study reveals that signs of antibody-mediated rejection can be detected as early as day 10 post-transplant, peaking at day 33, confirming the understanding that rejection reactions are aggressive yet progress slowly [1] - A dynamic tracking period of 61 days allowed the identification of a critical "treatment time window," and targeted therapeutic interventions have shown significant effects in suppressing immune attacks [1][2] Group 2 - By understanding specific immune interactions at the molecular level, the research enables the formulation of precise anti-rejection strategies, potentially increasing transplant survival rates [2] - The findings provide a roadmap for optimizing genetically edited pigs and developing new anti-rejection drugs, with genetically modified pig kidneys expected to enter clinical routine applications within ten years, pending regulatory approval [2] - The research identifies key intervention time windows, laying a solid foundation for developing more effective anti-rejection therapies and guiding future research directions [2]

Company Overview - Xiamen Aide Biological Technology Co., Ltd. specializes in tumor gene testing reagents, software, and supporting instruments, as well as providing testing services and drug clinical research services [1] - The main products include testing reagents, testing services, and drug clinical research services [1] Financial Performance - For Q1 2025, the company reported revenue of 272 million yuan, a year-on-year increase of 16.63% [1] - The net profit for the same period was 90.47 million yuan, reflecting a year-on-year growth of 40.92% [1] - The sales gross margin stood at 83.48% [1] Market Position - As of July 2, the company's stock closed at 21.28 yuan, down 1.48%, with a rolling PE ratio of 29.64 times [1] - The total market capitalization is 8.332 billion yuan [1] - In comparison to the medical device industry, which has an average PE ratio of 51.29 times and a median of 37.02 times, Aide Biological ranks 67th [1][2] Capital Flow - On July 2, the net outflow of main funds for Aide Biological was 11.87 million yuan, with a total outflow of 19.57 million yuan over the past five days [1]

临床医学 、 生命科学、 生物学、生物医学工程、药学等相关专业。 复旦大学宋振举教授课题组招聘博士后 宋振举教授简介 宋振举 ， 复 旦大学附属中山医院急诊科主任医师、博士研究生导师，复旦大学附属中山医院副院长，复 旦大学附属金山医院院长，上海市急危重症临床研究中心主任，国家重点研发计划首席科学家，上海市肺 部炎症与损伤重点实验室副主任 , 上海市重大传染病和生物安全研究院双聘PI ， 国家临床重点专科负责人 。中华医学会急诊医学分会第九届青年委员会副主任委员，中华医学会急诊医学分会危重病学副组长，中 国医药教育协会急诊医学专科分会副主任委员 , 中国医学救援协会生命支持技术分会第一届理事会副会长 。 《中国临床医学》 和《元宇宙医学》杂志副主编， 《中华急诊医学杂志》通讯编委、《 World Journal of Emergency Medicine 》 编委。近 5年主持国家级课题5项，省部级课题3项；通讯作者在Nature Immunology, National Science Review, Nature Communications等国际知名期刊发表论文18篇，发表专 家共识5项，申请专利27项， ...